The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

  • Lowest Price Guaranteed From USD 3,499

  • Published
    March 2018

  • Pages
    520

  • View Count
    4256

Example Insights

  1. Over 500 companies across the world are currently offering pharmaceutical contract manufacturing services. Service providers offer a variety of pharmaceutical services; these range from formulation services, stability studies / stability testing, method development / analytical development / process development, clinical trial material manufacturing, scale-up, registration batch manufacturing, commercial production and packaging and labelling service. It is worth highlighting that several CMOs offer end-to-end services across all scales of operations; examples of such players include (in alphabetical order) Aenova, Alcami® Pharma, AMRI, Catalent®, CMIC Group, CordenPharma, Dalton Pharma Services, Fresenius Kabi, Hovione, Recipharm, Siegfried and WuXi AppTec.
  2. At present, the market is highly fragmented and is a mix of established companies (>200 employees, 52%), mid-sized companies (>50 employees, 26%) and small-sized companies (<50 employees, 21%) offering contract manufacturing services at various scales of operations. 46% of the companies are specifically providing FDF manufacturing services while 23% are specifically providing API manufacturing services. The remaining 31% of the companies offer both API and FDF contract manufacturing services.
  3. Regulatory authorities play an active role in making pharmaceutical industry one of the most highly regulated industries across the world. We observed that 79% of the CMOs have received operational approval and certification from the USFDA. This is followed by the companies that have received operational approval from the European Medicines Agency (33%), World Health Organization (30%) and UK Medicines and Healthcare products Regulatory Agency (20%). In addition, several CMOs have sought / received operational approval and certification from the regulatory bodies in other regions such as Australia, Brazil, China, Canada, India and South Africa.
  4. The current global contract pharmaceutical installed manufacturing capacity is estimated to be over 115 million liters. It is also worth mentioning that, amongst all the CMOs we evaluated, established CMOs contribute a significant proportion (78%) to the overall supply. Having said that, relatively small-sized or mid-sized companies are one of the key driving forces behind the heightened pace of pharmaceutical research and development. In addition, of the total installed capacity, over 75% of the total installed capacity is being used for both clinical and commercial production.
  5. Amidst increasing competition in the outsourcing domain, CMOs are actively investigating and adopting several innovative tools and strategies in order to advance the development of drugs with higher success rates and improve the overall productivity. Examples of such strategies (in no specific order) include usage of big data analytics, green chemistry (such as solvent reduction and replacement, refining a chemical route and biocatalysis to optimize API synthesis), continuous process manufacturing system, digital medicines, 3D printed pill technologies, robotics and automation instruments for packaging, adoption of improved waste management and environment friendly strategies along with the integration of cybersecurity solutions.
  6. Driven by increasing global demand and rapid approval of small molecule drugs by the USFDA, we expect the overall contract manufacturing market in the pharmaceutical domain to grow at an annualized rate of 4.8% between 2018 and 2028. The growth is likely to be higher in emerging markets of Asia-Pacific and rest of the world.
  7. In terms of type of API product (branded and generic), generic APIs hold the current major share of the market (84%) while the remaining share (16%) of the total outsourced API market is occupied by branded APIs. Within the contract FDF market, solid dose compounds (~50%) currently dominate the market followed by injectables (33%) and semi-solid / liquid compounds (17%). The future growth is likely to be driven by injectables dose manufacturing primarily due to increased focus on complex disease areas and the growing trend of self-administration.
  8. In terms of type of FDF, the most popular type is primary packaging of tablets / capsules / blisters, which currently hold 26% of the total FDF contract manufacturing market. This is further followed by glass / plastic / dropper bottles (21%) and vials / cartridge (15%). Other packaging forms such as ampoules, ointments / gels / tubes and sachets / pouches / infusion bags also hold a considerable share of the current FDF contract manufacturing market.
  9. North America currently holds the largest share (34.3%) in the overall contract manufacturing market and is anticipated to continue to grow at an annualized growth rate of 2.9%. This is followed by Asia-Pacific and Europe that account for 34.1% and 30.3% share of the overall contract manufacturing market, respectively. However, markets in Asia-Pacific are expected to grow at a significantly higher CAGR of 7.1%, owing to inherent advantages such as relatively low labor costs and less stringent regulatory constraints.

Overview

Trends related to manufacturing have changed completely in the last 10-12 years. Large pharma companies are rapidly expanding their offerings by acquiring smaller companies. At the same time, some players are transferring their R&D and manufacturing operations to smaller players, while themselves operating as virtual companies.

-President and CEO, US based mid-sized CMO

The present pipeline of pharmaceutical products is increasingly complex and requires specialized facilities, equipment and operational expertise. Small molecule drugs account for nearly 90% of the therapeutics in the pharmaceutical market. In fact, in 2017, FDA’s Center for Drug Evaluation and Research approved 34 small molecule drugs; this represents an annual growth of nearly 56%, signifying the growing importance of contract manufacturing in the overall pharmaceutical industry. The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. The aforementioned constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Third-party service providers are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market.

Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. Since 2000, close to 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.

The current global CMO market is highly fragmented but characterized by multiple acquisitions and mergers as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to start offering end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings.

Despite the fact that the pharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and will grant a competitive edge to certain CMOs over other stakeholders in the industry. However, given the ongoing innovation in production technologies and the steadily evolving pipeline of small molecules, the pressure on the contract manufacturing industry is expected to increase in the coming years. This is likely to require CMOs to devise and implement different business strategies and models in order to cope with the evolving demand.

 

Scope of Report

The ‘Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028’ report provides a comprehensive study on the current scenario of contract manufacturing services related to pharmaceutical products. The study features an in-depth analysis, highlighting the capabilities of a diverse set of pharmaceutical CMOs. Amongst other elements, the report features:

  • An overview of the current market landscape, featuring a comprehensive list of over 500 active CMOs, and detailed analysis of manufacturing service providers based on a number of parameters, such as geographical location of CMOs, type of business segments (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), type of FDFs manufactured (solids, liquids / semi-solids and injectables), scale of operation (pilot, clinical, and commercial), type of service(s) offered, specific location of manufacturing facilities (country-wise) and  types of primary packaging forms being manufactured (tablet / capsule / blister packing, ointment /  gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe). In addition, the report features a year-wise analysis of the number of CMOs that have been established over the past five decades, based on the year in which they were founded.
  • An analysis of the most active regions, based on the presence of contract manufacturers; the report contains schematic world map representations indicating the geographical location of key hubs with respect to contract manufacturing activity across the globe.
  • A detailed discussion of various guidelines laid down by major regulatory bodies in different countries. The report also includes a comprehensive assessment of over 500 CMOs, including details of operational approvals and certifications received by each firm. In addition, the report highlights the relative popularity of the key regulatory bodies across the globe based on the number of companies which comply to the guidelines laid down by each of these authorities. The report also features an insightful multi-dimensional bubble analysis, featuring a comparison of the current regulatory scenario in key geographies across the globe.
  • Elaborate profiles of key players that offer end-to-end services ranging from product design and discovery to final packaging. Each profile provides an overview of the company, its financial performance (if available), information on its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are currently offering contract manufacturing services for large molecules.
  • A comprehensive set of analyses on pharmaceutical contract manufacturing service providers featuring three schematic representations, which include [A] a heat map analysis featuring the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of  location of headquarters, year of establishment and number of employees, [B] a geographical landscape analysis,highlighting those CMOs that have a significantly wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees and the type of business operation.
  • A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the industry. The analysis takes into consideration the actual capacities of small-sized, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. The study highlights the distribution of global capacity by scale of operation (clinical, commercial, both), regions (North America, Europe, Asia-Pacific, rest of the world) and specific countries within North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution. It also offers a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
  • A review of emerging trends, including the increase in outsourcing activity in emerging markets, shift towards an integrated business model through expansions and consolidation, introduction of innovative technologies / continuous processing systems, use of big data and advanced analytics to improve the manufacturing process and adoption of cybersecurity solutions to protect confidential customer data. It also includes a detailed discussion on the various growth drivers, such as increasing demand for biologics, biosimilars, and highly potent and cytotoxic drugs.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical contract manufacturing market over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2028. In addition, we have provided the likely distribution of the market based on [A] type of business segment (API and FDF), [B] regional evolution of the market covering North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large companies). To account for the uncertainties associated with the growth of pharmaceutical contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following stakeholders:

  • Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea)
  • Thomas Früh (CEO, Bachem)
  • Piyush Desai (Director, Operations, Sovereign Pharma)
  • Claire Otjes (Assistant Manager, Marketing, Batavia Biosciences)
  • Dietmar Katinger (CEO, Polymun Scientific)
  • Birgit Schwab (Senior Manager, Strategic Marketing, Rentschler Biopharma)
  • Sebastian Schuck (Head, Business Development, WACKER Biotech)
  • Bhaskar Venepalli (President and CEO, CiVentiChem)
  • Roberto Margarita (Director, Business Development, CordenPharma)
  • Allison Vavala (Senior Manager, Business Development, Helsinn Group)
  • Kevin Daley (Director, Pharmaceuticals Marketing, Novasep)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing market, in the short-mid and long term.

Chapter 3  is a general introduction to various type of manufacturers in the pharmaceutical market. It features a brief overview of the concept of contract manufacturing and a general discussion on the evolution of the contract services in the pharmaceutical industry. It also includes a detailed discussion on the need for outsourcing in this domain. Further, we have provided a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry, till date. We have also presented an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the market.

Chapter 4  provides a comprehensive view on the global landscape of pharmaceutical CMOs. It includes information related to over 500 CMOs that are currently active in the pharmaceutical industry. It features an in-depth market review, including regional distribution, analysis by company size and year of establishment, type of business segments, type of FDFs manufactured, scale of operation, type of service(s) offered, location of manufacturing facilities and different types of primary packaging forms being manufactured.

Chapter 5  featuresa detailed discussion on the guidelines laid down by major regulatory bodies across different countries. The report also includes an assessment of over 500 CMOs related to the operational approvals and certifications received from various regulatory bodies, along with a schematic world map representation, highlighting the relative popularity (in terms of the number of companies that are operating in compliance to the guidelines laid down by each regulatory authority) of the key regulatory bodies across the globe. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies across the globe.

Chapter 6  features detailed profiles of some of the key players that are active in the pharmaceutical contract manufacturing market and are acting as one-stop-shops. Each profile presents a brief overview of the company, its financial information  (if available) , details related to its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 7  is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are offering contract manufacturing services for large molecules / biologics.

Chapter 8  presents a collection of key insights derived from the study. It includes a heat map analysis, highlighting the number of integrated players based on the location of their headquarters, year of establishment and number of employees. The chapter also features a geographical landscape analysis, wherein pharmaceutical CMOs having a relatively wide geographical reach, are highlighted. For this analysis, we have also highlighted the geographical locations of the aforementioned companies on a world map. In addition, the chapter includes a schematic grid analysis, featuring the distribution of pharmaceutical CMOs based on location of their headquarters, number of employees and the type of business operations (API / FDF / both).

Chapter 9  features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of pharmaceutical products. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized, large and very large CMOs, distributed across their respective facilities. The results of this analysis were used to establish an accurate opinion on outsourcing capabilities of the CMOs across different geographies / regions and scales of operation (clinical, commercial and both). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 10  provides a comprehensive market forecast analysis, highlighting the future potential of pharmaceutical contract manufacturing till the year 2028. It features the likely distribution of the market based on [A] type of business segment (API and FDF), [B] region (North America, Europe, Asia-Pacific and rest of the world) and further distribution by major countries within the aforementioned regions, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment /  gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large-companies).

Chapter 11  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under a comprehensive SWOT framework. The chapter also highlights a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall pharmaceutical industry.

Chapter 12  is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of pharmaceutical CMOs in the foreseen future.

Chapter 13  is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea), Thomas Früh (CEO, Bachem), Piyush Desai (Director, Operations, Sovereign Pharma), Claire Otjes (Assistant Manager, Marketing, Batavia Biosciences), Dietmar Katinger (CEO, Polymun Scientific), Birgit Schwab (Senior Manager, Strategic Marketing, Rentschler Biopharma), Sebastian Schuck (Head, Business Development, WACKER Biotech), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Senior Manager, Business Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep).

Chapter 14  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional CMOs
3.4.2. Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Software Service Providers
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry
 
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered
 
5. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Bubble Analysis: Regional Regulatory Summary
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops
 
6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Financial Information
6.4.1.4. Manufacturing Capabilities and Facilities
6.4.1.5. Recent Developments
6.4.1.6. Future Outlook
 
6.4.2. Catalent Pharma Solutions
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Financial Information
6.4.2.4. Manufacturing Capabilities and Facilities
6.4.2.5. Recent Developments
6.4.2.6. Future Outlook
 
6.4.3. DPT Laboratories
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments
6.4.3.5. Future Outlook
 
6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon)
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Financial Information
6.4.4.4. Manufacturing Capabilities and Facilities
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
 
6.5. Players in Europe
6.5.1. Aenova Group
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio
6.5.1.3. Financial Information
6.5.1.4. Manufacturing Capabilities and Facilities
6.5.1.5. Recent Developments
6.5.1.6. Future Outlook
 
6.5.2. Almac Group
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.5.2.3. Recent Developments
6.5.2.4. Future Outlook
 
6.5.3. CordenPharma
6.5.3.1. Company Overview
6.5.3.2. Service Portfolio
6.5.3.3. Manufacturing Capabilities and Facilities
6.5.3.4. Recent Developments
6.5.3.5. Future Outlook
 
6.5.4. Fresenius Kabi
6.5.4.1. Company Overview
6.5.4.2. Service Portfolio
6.5.4.3. Financial Information
6.5.4.4. Manufacturing Capabilities and Facilities
6.5.4.5. Recent Developments
6.5.4.6. Future Outlook
 
6.5.5. Glatt®
6.5.5.1. Company Overview
6.5.5.2. Service Portfolio
6.5.5.3. Manufacturing Capabilities and Facilities
6.5.5.4. Recent Developments
6.5.5.5. Future Outlook
 
6.5.6. Groupe SYNERLAB
6.5.6.1. Company Overview
6.5.6.2. Service Portfolio
6.5.6.3. Manufacturing Capabilities and Facilities
6.5.6.4. Future Outlook
6.5.7. Hovione
6.5.7.1. Company Overview
6.5.7.2. Service Portfolio
6.5.7.3. Manufacturing Capabilities and Facilities
6.5.7.4. Recent Developments
6.5.7.5. Future Outlook
 
6.5.8. Recipharm
6.5.8.1. Company Overview
6.5.8.2. Service Portfolio
6.5.8.3. Financial Information
6.5.8.4. Manufacturing Capabilities and Facilities
6.5.8.5. Recent Developments
6.5.8.6. Future Outlook
 
6.5.9. Siegfried
6.5.9.1. Company Overview
6.5.9.2. Service Portfolio
6.5.9.3. Financial Information
6.5.9.4. Manufacturing Capabilities and Facilities
6.5.9.5. Recent Developments
6.5.9.6. Future Outlook
6.6. Players in Asia-Pacific
 
6.6.1. CMIC Group
6.6.1.1. Company Overview
6.6.1.2. Service Portfolio
6.6.1.3. Financial Information
6.6.1.4. Manufacturing Capabilities and Facilities
6.6.1.5. Recent Developments
6.6.1.6. Future Outlook
6.6.2. Nectar Lifesciences
6.6.2.1. Company Overview
6.6.2.2. Service Portfolio
6.6.2.3. Financial Information
6.6.2.4. Manufacturing Capabilities and Facilities
6.6.2.5. Future Outlook
 
6.6.3. WuXi AppTec
6.6.3.1. Company Overview
6.6.3.2. Service Portfolio
6.6.3.3. Financial Information
6.6.3.4. Manufacturing Capabilities and Facilities
6.6.3.5. Recent Developments
6.6.3.6. Future Outlook
 
7. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
7.1. Chapter Overview
7.2. Small Molecules and Large Molecules Drugs / Therapies
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs
 
8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Multipotentialite Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment
 
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks
 
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Pharmaceutical Contract Manufacturing Market, 2018-2028
10.3.1. Pharmaceutical Contract Manufacturing Market for API Manufacturing, 2018-2028
10.3.2. Pharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2018-2028
10.4. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions
10.4.1. Pharmaceutical Contract Manufacturing Market in North America, 2018-2028
10.4.1.1. Pharmaceutical Contract Manufacturing Market in the US, 2018-2028
10.4.1.2. Pharmaceutical Contract Manufacturing Market in Canada, 2018-2028
10.4.1.3. Pharmaceutical Contract Manufacturing Market in Mexico, 2018-2028
10.4.2. Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028
10.4.2.1. Pharmaceutical Contract Manufacturing Market in Italy, 2018-2028
10.4.2.2. Pharmaceutical Contract Manufacturing Market in Germany, 2018-2028
10.4.2.3. Pharmaceutical Contract Manufacturing Market in France, 2018-2028
10.4.2.4. Pharmaceutical Contract Manufacturing Market in Spain, 2018-2028
10.4.2.5. Pharmaceutical Contract Manufacturing Market in the UK, 2018-2028
10.4.2.6. Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2018-2028
10.4.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028
10.4.3.1. Pharmaceutical Contract Manufacturing Market in India, 2018-2028
10.4.3.2. Pharmaceutical Contract Manufacturing Market in China, 2018-2028
10.4.3.3. Pharmaceutical Contract Manufacturing Market in Japan, 2018-2028
10.4.3.4. Pharmaceutical Contract Manufacturing Market in Australia, 2018-2028
10.4.3.5. Pharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2018-2028
10.4.4. Pharmaceutical Contract Manufacturing Market in Rest of the World, 2018-2028
10.4.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions
10.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product
10.6. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API
10.7. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF
10.7.1. Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028
10.7.2. Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028
10.7.3. Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028
10.8. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form
10.8.1. Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028
10.8.2. Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028
10.8.3. Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028
10.8.4. Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028
10.8.5. Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028
10.8.6. Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028
10.8.7. Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028
10.9. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers
10.10 Concluding Remarks
 
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors
 
12. FUTURE OF THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Expansion of Capabilities and Emergence of One-Stop-Shops
12.5. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.6. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.7. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.8. Concluding Remarks
 
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Ajinomoto Althea
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Scott Goldstein, Associate Director, Drug Product Manufacturing
 
13.3. Bachem
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Fruh, Chief Executive Officer
 
13.4. Sovereign Pharma
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Piyush Desai, Director, Operations
 
13.5. Batavia Biosciences
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Claire Otjes, Assistant Marketing Manager
 
13.6. Polymun Scientific
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Dietmar Katinger, Chief Executive Officer
 
13.7. Rentschler Biopharma
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Birgit Schwab, Senior Manager Strategic Marketing
 
13.8. WACKER Biotech
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Sebastian Schuck, Head of Business Development
 
13.9. CiVentiChem
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
 
13.10. CordenPharma
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Roberto Margartia, Business Development Director
 
13.11. Helsinn Group
13.11.1. Company Snapshot
13.11.2. Interview Transcript: Allison Vavala, Senior Manager, Business Development
 
13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Types of Manufacturers in Contract Manufacturing Industry
Figure 3.2  Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3  Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4  Range of Services Offered by CMOs
Figure 3.5  Factors for Selecting a CMO Partner
Figure 4.1  Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2  Pharmaceutical CMOs: Distribution by Geographical Location
Figure 4.3  Pharmaceutical CMOs: Regional Hubs
Figure 4.4  Pharmaceutical CMOs: Distribution by Company Size
Figure 4.5  Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 4.6  Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 4.7  Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.8  Pharmaceutical CMOs: Distribution by Type of Service Offering
Figure 4.9  Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.10  Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Figure 5.1  Key Regulatory Requirements for CMOs and CROs in India
Figure 5.2  Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Figure 5.3  Bubble Analysis: Regional Regulatory Summary
Figure 6.1  AMRI: Service Portfolio
Figure 6.2  AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.3  AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.4  Catalent® Pharma Solutions: Service Portfolio
Figure 6.5  Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Figure 6.6  DPT® Laboratories: Service Portfolio
Figure 6.7  Patheon®: Service Portfolio
Figure 6.8  Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Figure 6.9  Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Figure 6.10  Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.11  Patheon®: Revenues by Business Segments, 2016 (USD Million)
Figure 6.12  Aenova Group: Service Portfolio
Figure 6.13  Almac Group: Service Portfolio
Figure 6.14  CordenPharma: Service Portfolio
Figure 6.15  Fresenius Kabi: Service Portfolio
Figure 6.16  Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.17  Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Figure 6.18  Glatt®: Service Portfolio
Figure 6.19  Groupe SYNERLAB: Service Portfolio
Figure 6.20  Hovione: Service Portfolio
Figure 6.21  Recipharm: Service Portfolio
Figure 6.22  Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Figure 6.23  Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Figure 6.24  Siegfried: Service Portfolio
Figure 6.25  Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Figure 6.26  Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Figure 6.27  CMIC Group: Service Portfolio
Figure 6.28  CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Figure 6.29  Nectar Lifesciences: Service Portfolio
Figure 6.30  Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Figure 6.31  WuXi AppTec: Service Portfolio
Figure 6.32  STA Pharmaceuticals (API Service Provider, WuXi AppTec): Service Portfolio
Figure 6.33  WuXi AppTec: Revenues (USD Million)
Figure 7.1  Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 7.2  Small Molecules versus Large Molecules: Comparison of Manufacturing Processes
Figure 7.3  Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Figure 8.1  Multipotentialite Service Providers, Heat Map Analysis: Distribution by Geography, Company Size and Year of Establishment
Figure 8.2  Pharmaceutical CMOs: Geographical Landscape Analysis by Location of Manufacturing Facilities
Figure 8.3  Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Figure 9.1  Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Figure 9.2  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Figure 9.3  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Figure 9.5  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 9.6  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 10.1  Pharmaceutical Contract Manufacturing: Market Forecast Approach
Figure 10.2  Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Figure 10.3  Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Figure 10.4  Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.5  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.6  Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Figure 10.7  Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Figure 10.8  Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Base Scenario (USD Billion)
Figure 10.9  Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Base Scenario (USD Billion)
Figure 10.10 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Base Scenario (USD Billion)
Figure 10.11  Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Figure 10.12  Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Base Scenario (USD Billion)
Figure 10.13  Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Base Scenario (USD Billion)
Figure 10.14  Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Base Scenario (USD Billion)
Figure 10.15  Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Base Scenario (USD Billion)
Figure 10.16  Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Base Scenario (USD Billion)
Figure 10.17  Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Europe, Base Scenario (USD Billion)
Figure 10.18  Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Figure 10.19  Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Base Scenario (USD Billion)
Figure 10.20  Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Base Scenario (USD Billion)
Figure 10.21  Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Base Scenario (USD Billion)
Figure 10.22  Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Base Scenario (USD Billion)
Figure 10.23  Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Asia-Pacific, Base Scenario (USD Billion)
Figure 10.24  Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Figure 10.25 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Figure 10.26 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Figure 10.27  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Figure 10.28  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product and Regions, Base Scenario (USD Billion)
Figure 10.29  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Figure 10.30  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Figure 10.31  Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.32  Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.33  Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.34  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Figure 10.35  Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028: Base Scenario (USD Billion)
Figure 10.36  Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028: Base Scenario (USD Billion)
Figure 10.37  Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028: Base Scenario (USD Billion)
Figure 10.38  Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028: Base Scenario (USD Billion)
Figure 10.39  Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028: Base Scenario (USD Billion)
Figure 10.40  Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028: Base Scenario (USD Billion)
Figure 10.41  Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028: Base Scenario (USD Billion)
Figure 10.42  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Figure 10.43 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
Figure 11.1  Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 11.2  Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 11.3  Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 11.4  Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 11.5  Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 11.6  Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1  Future of Pharmaceutical Contract Manufacturing Market
Figure 12.2  Emerging Markets in Pharmaceutical Contract Manufacturing Industry

List of Tables

Table 4.1  Pharmaceutical CMOs: List of Industry Players 
Table 4.2  Pharmaceutical CMOs: Information on Type of FDF Offered
Table 4.3  Pharmaceutical CMOs: Information on Scale of Operation 
Table 4.4  Pharmaceutical CMOs: Information on Type of Service Offering
Table 4.5  Pharmaceutical CMOs: Information on Location of Manufacturing Facilities 
Table 4.6  Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.1  FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 5.2  Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 5.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 6.1  Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 6.2  AMRI: Manufacturing Facilities
Table 6.3  AMRI: Sterile Manufacturing Facilities 
Table 6.4  AMRI: Recent Collaborations
Table 6.5  AMRI: Recent Expansions
Table 6.6  Catalent® Pharma Solutions: Manufacturing Facilities 
Table 6.7  Catalent® Pharma Solutions: Recent Collaborations
Table 6.8  Catalent® Pharma Solutions: Recent Expansions
Table 6.9  DPT® Laboratories: Manufacturing Facilities 
Table 6.10  DPT® Laboratories: Recent Collaborations
Table 6.11  DPT® Laboratories: Recent Expansions 
Table 6.12  Patheon®: Manufacturing Facilities 
Table 6.13  Patheon®: Recent Collaborations 
Table 6.14  Patheon®: Recent Expansions
Table 6.15  Aenova Group: Manufacturing Facilities 
Table 6.16  Aenova Group: Drug Product Manufacturing Capabilities 
Table 6.17  Aenova Group: Recent Expansions
Table 6.18  Almac Group: Recent Collaborations 
Table 6.19  Almac Group: Recent Expansions
Table 6.20  CordenPharma: Manufacturing Facilities 
Table 6.21  CordenPharma: Recent Collaborations
Table 6.22  CordenPharma: Recent Expansions
Table 6.23  Fresenius Kabi: Manufacturing Facilities
Table 6.24  Fresenius Kabi: Packaging Capabilities
Table 6.25  Fresenius Kabi: Recent Collaborations
Table 6.26  Fresenius Kabi: Recent Expansions
Table 6.27  Glatt®: Manufacturing Facilities
Table 6.28  Glatt®: Recent Expansions
Table 6.29  Groupe SYNERLAB: Manufacturing Facilities 
Table 6.30  Hovione: Manufacturing Facilities
Table 6.31  Hovione: Recent Collaborations
Table 6.32  Hovione: Recent Expansions
Table 6.33  Recipharm: Manufacturing Facilities 
Table 6.34  Recipharm: Recent Collaborations
Table 6.35  Recipharm: Recent Expansions
Table 6.36  Siegfried: Manufacturing Facilities 
Table 6.37  Siegfried: Recent Collaborations
Table 6.38  CMIC Group: Manufacturing Facilities 
Table 6.39  CMIC Group: Recent Collaborations
Table 6.40  CMIC Group: Recent Expansions
Table 6.41  Nectar Lifesciences: Manufacturing Facilities 
Table 6.42  WuXi AppTec: Manufacturing Facilities
Table 6.43  WuXi AppTec: Recent Collaborations
Table 6.44  WuXi AppTec: Recent Expansions
Table 7.1  Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 7.2  List of Biopharmaceutical CMOs
Table 9.1  Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 9.2  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1  Ajinomoto Althea: Key Highlights
Table 13.2  Bachem: Key Highlights
Table 13.3  Sovereign Pharma: Key Highlights
Table 13.4  Batavia Biosciences: Key Highlights
Table 13.5  Polymun Scientific: Key Highlights
Table 13.6  Rentschler Biopharma: Key Highlights
Table 13.7  WACKER Biotech: Key Highlights
Table 13.8  CiVentiChem: Key Highlights
Table 13.9  Helsinn Group: Key Highlights
Table 13.10  Novasep: Key Highlights
Table 14.1  Pharmaceutical CMOs: Distribution by Year of Establishment
Table 14.2  Pharmaceutical CMOs: Distribution by Geographical Location
Table 14.3  Pharmaceutical CMOs: Distribution by Company Size
Table 14.4  Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 14.5  Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 14.6  Pharmaceutical CMOs: Distribution by Scale of Operation
Table 14.7  Pharmaceutical CMOs: Distribution by Service Offerings
Table 14.8  Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Table 14.9  Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Table 14.10  Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Table 14.11  AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.12 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 14.13  Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Table 14.14  Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Table 14.15  Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Table 14.16  Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Table 14.17  Patheon®: Revenues by Business Segments, 2016 (USD Million)
Table 14.18  Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Table 14.19  Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Table 14.20  Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Table 14.21  Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Table 14.22  Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Table 14.23  Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Table 14.24  CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Table 14.25  Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Table 14.26  WuXi AppTec: Revenues (USD Million)
Table 14.27  Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 14.28  Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 14.29 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 14.30  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 14.31  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Table 14.32  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 14.33  Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 14.34  Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Conservative Scenario (USD Billion)
Table 14.35  Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Table 14.36  Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.37  Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48  Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Table 14.39  Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.40  Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Conservative Scenario (USD Billion)
Table 14.41  Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Table 14.42  Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.43 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Conservative Scenario (USD Billion)
Table 14.44 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Table 14.45 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 14.46 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Table 14.47  Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48  Pharmaceutical Contract Manufacturing Market in North America, 2018-2028:  Base Scenario (USD Billion)
Table 14.49  Pharmaceutical Contract Manufacturing Market in North America, 2018-2028:  Optimistic Scenario (USD Billion)
Table 14.50  Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Conservative Scenario (USD Billion)
Table 14.51  Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028:  Base Scenario (USD Billion)
Table 14.52  Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028:  Optimistic Scenario (USD Billion)
Table 14.53  Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Conservative Scenario (USD Billion)
Table 14.54  Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Base Scenario (USD Billion)
Table 14.55  Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.56 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Table 14.57 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Table 14.58 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Conservative Scenario (USD Billion)
Table 14.59 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Table 14.60 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Types of API Product, Optimistic Scenario (USD Billion)
Table 14.61 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Conservative Scenario (USD Billion)
Table 14.62 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Base Scenario (USD Billion)
Table 14.63 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Type of API Product in North America, Optimistic Scenario (USD Billion)
Table 14.64 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Conservative Scenario (USD Billion)
Table 14.65 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Base Scenario (USD Billion)
Table 14.66 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Optimistic Scenario (USD Billion)
Table 14.67 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.68 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Base Scenario (USD Billion)
Table 14.69 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.70 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Conservative Scenario (USD Billion)
Table 14.71 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Base Scenario (USD Billion)
Table 14.72 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Optimistic Scenario (USD Billion)
Table 14.73 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Conservative Scenario (USD Billion)
Table 14.74 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Table 14.75  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Optimistic Scenario (USD Billion)
Table 14.76 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Conservative Scenario (USD Billion)
Table 14.77 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Table 14.78 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Optimistic Scenario (USD Billion)
Table 14.79 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Conservative Scenario (USD Billion)
Table 14.80 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Table 14.81 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Optimistic Scenario (USD Billion)
Table 14.82  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Conservative Scenario (USD Billion)
Table 14.83  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Table 14.84  Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Optimistic Scenario (USD Billion)
Table 14.85 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report: 

  1. 3P Biopharmaceuticals
  2. A&Z Pharmaceutical
  3. A. S. Joshi & Company
  4. Aalto Scientific
  5. Aarti Industries
  6. Abbott
  7. AbbVie 
  8. ABL
  9. Abzena
  10. Accra Pac India
  11. ACES Pharma
  12. Acino International
  13. ACS Dobfar
  14. Actiza Pharmaceutical
  15. Adar Biotech
  16. Admac Formulations
  17. Aenova 
  18. Aesica Pharmaceuticals
  19. Affinity Life Sciences
  20. Afton Scientific
  21. Agno Pharma
  22. AiPing Pharmaceutical
  23. Air Water
  24. Ajinomoto Althea
  25. Ajinomoto OmniChem
  26. Akorn
  27. Akums Drugs & Pharmaceuticals
  28. Al Bahja Group
  29. Aland (Jiangsu) Nutraceutical
  30. Albany Molecular Research (AMRI)
  31. Albatros Pharmaceuticals
  32. Albemarle 
  33. AlbyPharma
  34. Alcami
  35. Alcatel-Lucent 
  36. Aldevron
  37. Alembic Pharmaceuticals
  38. Alkermes®
  39. AllChem Laboratories
  40. Alliance Medical Products
  41. Almac Pharma 
  42. Alpax Pharmaceutical
  43. Alphora Research 
  44. Alps Pharmaceutical 
  45. Altaris Capital Partners
  46. ALTHEA Pharma
  47. Amanta Healthcare
  48. Amatsigroup
  49. Ambica Pharma Sales
  50. AmbioPharm
  51. AMEGA Biotech
  52. American Antibiotics
  53. Amgen®
  54. Ami Lifescience
  55. Amman Pharmaceutical Industries
  56. Amneal Pharmaceuticals
  57. Amoli Organics 
  58. AMPAC Fine Chemicals 
  59. Angelini 
  60. Anhui Biochem United Pharmaceutical
  61. Ankur Drugs and Pharma
  62. Anogen
  63. Anqiu Lu'an Pharmaceutical 
  64. apceth Biopharma
  65. Apex Pharmaceuticals
  66. Apicore Pharmaceuticals
  67. Apiscent Labs
  68. APL
  69. Apotex Fermentation 
  70. Aptuit
  71. Arabio
  72. Arbro Pharmaceuticals
  73. Arch Pharmalabs
  74. Arevipharma
  75. Arran Chemical Company
  76. Arvincare 
  77. Asahi Glass Company (AGC)
  78. Asahi Kasei Finechem 
  79. Ashford Pharmaceutical Laboratories
  80. Aspen Pharmacare Holdings
  81. Aster Pharma
  82. Asymchem Laboratories 
  83. ATRA Pharmaceuticals
  84. AURA Biotechnologies
  85. Aurelius
  86. Aurobindo Pharma 
  87. Ausler Snovy Healthcare
  88. AustarPharma
  89. Austin Pharmaceuticals
  90. AutekBio
  91. Avecia
  92. Avid Bioservices
  93. Avra Laboratories 
  94. Avyukt Pharmaceuticals
  95. Axa Parenterals
  96. Baccinex
  97. Bachem 
  98. Bal Pharma
  99. Batavia Biosciences
  100. Bausch & Lomb
  101. Baxil Pharma
  102. Baxter BioPharma Solutions
  103. Bayer 
  104. BCN Peptides
  105. Beach Products
  106. Becton Dickinson
  107. Beijing Second Pharmaceutical
  108. Belcher Pharmaceuticals
  109. Belco Pharma
  110. Beltapharm
  111. Bennet Pharmaceuticals
  112. BePharBel
  113. Beximco Pharmaceuticals
  114. Bharat Pharmaceuticals
  115. Bharat Serums and Vaccines
  116. BIBITEC
  117. BINEX
  118. Bio Elpida
  119. BioCell
  120. BioClin Laboratories
  121. Biocon
  122. BioConnection
  123. BIOFABRI
  124. Bio-Garten 
  125. Biogen
  126. Biological E
  127. BioMARC
  128. Biomatik
  129. Biomay
  130. BIOMEVA
  131. Bio-Pharm
  132. BioPharmaceuticals Australia
  133. Bioserv
  134. BioSynergy
  135. Bio-Synthesis
  136. Biotech Vision Care
  137. BioTechLogic
  138. BioTechnique™
  139. Biotechpharma
  140. Biovectra
  141. Biovian
  142. Bluepharma
  143. Blueprint Medicines
  144. Boehringer Ingelheim BioXcellence
  145. Bonarum Pharma
  146. Brammer Bio
  147. Brassica Pharma
  148. Brazilian Health Regulatory Agency (ANVISA)
  149. Broad Institute of MIT and Harvard
  150. Broad Pharmaceutical
  151. Bruker Daltonics 
  152. Bruschettini
  153. Bryllan
  154. BSP Pharmaceuticals
  155. C & O Pharmaceutical Technology
  156. Cadila Pharmaceuticals
  157. Calyx Chemicals & Pharmaceuticals
  158. Cambrex 
  159. Capgemini
  160. Caplin Point Laboratories
  161. Capsugel®
  162. CARBOGEN AMCIS
  163. Catalent® Pharma Solutions
  164. Cayman Chemical
  165. Cell and Gene Therapy Catapult
  166. Cell Culture Company
  167. Cell Essentials
  168. Cell Therapies
  169. CELLforCURE
  170. Cellin Technologies
  171. Celltech
  172. Celltrion
  173. Cellular Therapeutics
  174. Celonic
  175. Cenexi
  176. Centaur Pharmaceuticals
  177. Center for Biocatalysis and Bioprocessing, The University of Iowa
  178. Central Drugs Standard Control Organization (CDSCO)
  179. Century Pharmaceuticals
  180. CEPiA Sanofi
  181. Cerbios-Pharma
  182. CF Pharma
  183. Charles River Laboratories
  184. Chartwell Pharmaceuticals
  185. ChemCon 
  186. Chemi Peptides
  187. Chemigran
  188. ChemPacific
  189. ChemPartner
  190. Cherokee Pharma
  191. Chifeng Arker Pharmaceutical Technology
  192. China Chemical & Pharmaceutical (CCPC)
  193. China Food and Drug Administration (CFDA)
  194. Chiral Biosciences
  195. Chirogate International
  196. Chongqing Huapont Pharmaceutical
  197. Chromo Laboratories
  198. Chunghwa Chemical Synthesis & Biotech
  199. CinnaGen
  200. Ciron Group
  201. Cirrus Pharmaceuticals
  202. CiVentiChem
  203. Clinical Trial Consultants (CTC)
  204. Cloud Holdings
  205. CMC Biologics
  206. CMC Milling
  207. CMIC Group
  208. Coating Place
  209. Cobra Biologics
  210. COC Farmaceutici
  211. Cody Laboratories
  212. Cognate BioServices
  213. Columbia University
  214. Combino Pharm
  215. Comprehend Systems 
  216. Concord Biotech
  217. Concord Drugs
  218. Confab Laboratories
  219. Contract Coating
  220. Contract Pharmacal
  221. Cook Pharmica
  222. Corden BioChem
  223. CordenPharma
  224. CoreRx®
  225. CP Pharmaceuticals
  226. Creative® Biolabs
  227. CRELUX
  228. Cris Pharma
  229. Crown Laboratories
  230. CTX Lifesciences
  231. Custom Pharmaceuticals
  232. Cyalume® Speciality Products
  233. Cytovance® Biologics
  234. Daiichi Sankyo
  235. Daito Pharmaceutical
  236. Dalton Pharma Services
  237. Delavau Pharmaceutical Partners
  238. Delmar Chemicals
  239. Delpharm 
  240. Delta Laboratories
  241. Dermopartners
  242. DEVA Holding
  243. DFB Pharmaceuticals 
  244. Dhruv Life Sciences
  245. Dipharma Francis
  246. Dishman Group
  247. Divis Laboratories
  248. DM Pharma
  249. dmBio
  250. DOTTIKON EXCLUSIVE SYNTHESIS
  251. Douglas Pharmaceuticals
  252. DPT® Laboratories
  253. Dr. Reddy's Custom Pharmaceutical Services (CPS)
  254. Dupen Laboratories
  255. Dwarkesh Pharmaceuticals
  256. Eagle Pharmaceuticals 
  257. Eden Healthcare
  258. Ei-A Pharmaceutical SolutionWorks™
  259. EirGen Pharma
  260. EirGenix
  261. EL Laboratories
  262. Elite Pharmaceuticals
  263. Elli Lilly
  264. Embio
  265. Emcure Pharmaceuticals
  266. Emergent Biosolutions®
  267. Eminent Healthcare
  268. Enaltec Labs 
  269. Encap Drug Delivery
  270. Enrich Pharma
  271. Entema Laboratorios
  272. Entod Pharmaceuticals
  273. Epic Pharma
  274. EPTEK Technology 
  275. Ercros
  276. Eriochem
  277. Erregierre
  278. Esteve Química
  279. Ethypharm
  280. EuBiologics
  281. EUCODIS Bioscience
  282. EUFETS
  283. Eurogentec
  284. Euro-Med Laboratories
  285. European Medicines Agency (EMA)
  286. Euticals
  287. Evonik Industries
  288. Evotec
  289. Excella
  290. Exela Pharma Sciences
  291. Exostar
  292. Exova SL Pharma Labs
  293. F. I. S. Fabbrica Italiana Sintetici 
  294. Famar
  295. Famy Care
  296. Fareva®
  297. Farmabios®
  298. Farmak
  299. Farmhispania Group
  300. Farmigea
  301. FDC
  302. Fermion
  303. Ferndale Laboratories
  304. Finecure Pharmaceuticals
  305. FineTech Pharmaceuticals
  306. Flamingo Pharmaceuticals
  307. Flamma
  308. Fleming Laboratories
  309. Fluid Energy Processing and Equipment
  310. Fresenius Kabi 
  311. Fresenius Kabi Product Partnering
  312. FUJIFILM Diosynth Biotechnologies
  313. Fujimoto Chemicals
  314. Fusion Antibodies
  315. Future Pak
  316. G&W Laboratories 
  317. Gadea Pharmaceutical Group
  318. Gala Biotech
  319. Galentic Pharma
  320. Gattefossé
  321. GD Pharma
  322. GE Healthcare
  323. Gedeon Richter
  324. Gemini PharmChem Mannheim 
  325. Gene Transfer Vector Core (GTVC)
  326. GeneCure Biotechnologies
  327. Genentech
  328. GenIbet Biopharmaceuticals
  329. Gerresheimer
  330. Getz Pharma Research
  331. Gland Pharma
  332. Glatt®
  333. GlaxoSmithKline (GSK)
  334. Glenmark Pharmaceuticals
  335. Global Pharmatech
  336. Glochem Industries
  337. Glycotope Biotechnology
  338. GNH India
  339. goBalto
  340. Goodwin Biotechnology
  341. GP Pharm
  342. Grand River Aseptic Manufacturing
  343. Granules India
  344. Granules Omnichem
  345. GreenPak Biotech
  346. Grindeks
  347. Groupe PARIMA
  348. Groupe SYNERLAB
  349. Grupo Farmasierra
  350. GTCR
  351. GTP Technology
  352. Guardian Drug Company
  353. Hainan Poly Pharm
  354. Hainan Visum Pharmaceutical
  355. HALIX
  356. Halo Pharma
  357. Handok
  358. Hanford Pharmaceuticals
  359. Hangzhou Hysen Pharma
  360. Hangzhou Imaginechem
  361. Hangzhou Panyu Chemical
  362. Hanuchem Laboratories
  363. HD Biosciences
  364. Health Biotech
  365. Health Canada 
  366. Healthcare Pharmaceuticals
  367. Healthy Life Pharma
  368. Helios Pharmaceuticals
  369. Helsinn Group
  370. Hetero Drugs
  371. Hewlett-Packard® 
  372. HighRes Biosolutions
  373. Hikal
  374. Hikma Pharmaceuticals
  375. Histocell
  376. hollomet®
  377. Hong Kong Institute of Biotechnology
  378. Honson Pharmatech Group
  379. Horizon Pharma
  380. Hospira One2One
  381. Hovione
  382. Howard Hughes Medical Institute (HHMI)
  383. Hritik Chemicals
  384. Hubei Biocause Pharmaceutical
  385. IBM®
  386. Icagen
  387. ICROM
  388. IDT Australia
  389. IDT Biologika
  390. Illumina
  391. Indena 
  392. Indian Immunologicals
  393. Indoco Remedies
  394. Ind-Swift Laboratories
  395. Ingenus Pharmaceuticals
  396. Inke
  397. Inno Biologics
  398. Innova Captab
  399. Institute for Advanced Study (IAS) 
  400. INSYS Therapeutics
  401. Intas Pharmaceuticals
  402. Integrity Bio
  403. International Chemical Investors Group (ICIG)
  404. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
  405. Interquim
  406. Invent Farma
  407. inVentiv Health
  408. IPC Process-Center
  409. i-Pharmaceuticals
  410. Istituto Biochimico Italiano Giovanni Lorenzini
  411. IVAX Pharmaceuticals 
  412. J. B Chemicals & Pharmaceuticals
  413. Janssen Pharmaceuticals
  414. Japan CMO Association (JCMOA)
  415. JGL
  416. JHL Biotech
  417. Johnson & Johnson 
  418. Johnson Matthey
  419. JSC Olainfarm 
  420. Jubilant Life Sciences
  421. Julphar Gulf Pharmaceutical Industries
  422. Juno Therapeutics 
  423. JW Biotechnology
  424. Jyoti Capsulations
  425. KABS Pharmaceutical Services
  426. Kamat Pharmatech
  427. Kancera
  428. Karolinska University Hospital
  429. Katsura Chemical
  430. KBI Biopharma
  431. Kekule Pharma
  432. Kemwell Biopharma
  433. Keryx Biopharmaceuticals 
  434. Kilitch Healthcare
  435. Kongo Chemical
  436. Korten
  437. KP Pharmaceutical Technology
  438. Krebs Biochemicals & Industries
  439. KRS Global Biotechnology
  440. Kyowa Pharma Chemical
  441. Laboratório Edol
  442. Laboratorios Farmacéuticos ROVI
  443. Laboratorios Lesvi
  444. Laboratorios SALVAT
  445. Laccure
  446. Lameplast Group
  447. LAMPIRE Biological Laboratories
  448. Lannett
  449. Laurus Labs
  450. Lenovo™
  451. Lenus LifeCare
  452. LFB BIOMANUFACTURING
  453. LIDDS™
  454. Life Sciences Solutions
  455. Life Technologies™ 
  456. Lifekyor Pharmaceuticals
  457. Lloyd Laboratories
  458. LOBA Feinchemie
  459. Logos Pharma
  460. Lomapharm®
  461. Long Pharmaceuticals
  462. Lonza 
  463. LSNE Contract Manufacturing
  464. Luina Bio
  465. Luitpold Pharmaceuticals
  466. Lyne Laboratories
  467. MabPlex
  468. MacFarlan Smith
  469. Macter International
  470. Madras Pharmaceuticals
  471. Maine Biotechnology Services
  472. MAKCUR Laboratories
  473. Malik Lifesciences
  474. Malladi Drugs & Pharmaceuticals
  475. Manav Drugs
  476. Marchesini Group
  477. Marksans Pharma
  478. Massachusetts Institute of Technology
  479. MassBiologics
  480. MaSTherCell
  481. Maxcure Nutravedics
  482. Maya Biotech 
  483. Mayne Pharma Group
  484. McGuff Pharmaceuticals
  485. MDC Pharmaceuticals
  486. Meda Pharmaceuticals
  487. Medical Products Laboratories
  488. Medichem
  489. Medicines and Healthcare products Regulatory Agency (MHRA)
  490. Medicines Control Council (MCC)
  491. Medilux Laboratories
  492. Mediwin Pharmaceuticals
  493. Medix Biochemica
  494. MedPharm
  495. Menadiona
  496. Menarini Biotech
  497. Mercator Pharmaceutical Solutions
  498. Merck
  499. Meridian Life Science
  500. Meridian Medicare
  501. Merro Pharmaceutical
  502. Metrics Contract Services
  503. Metrochem API
  504. Micro Labs
  505. MicroBiopharm Japan
  506. Micro-Sphere 
  507. Mikart
  508. Ministry of Food and Drug Safety (MFDS)
  509. Ministry of Health, Labour and Welfare (MHLW)
  510. Mipharm
  511. Mitim
  512. MSN Laboratories
  513. Multi-Pack Solutions
  514. Murty Pharmaceuticals
  515. Mycenax Biotech
  516. Mylan®
  517. Nakoda Chemicals
  518. Nanjing Pharmatechs
  519. NATCO Pharma
  520. National Center for Advancing Translational Sciences 
  521. National Institutes of Health 
  522. Nectar Lifesciences
  523. NEISS Labs
  524. Nephron Pharmaceuticals
  525. NerPharMa
  526. Neuland Laboratories
  527. New York Center for Nanomedicine Research 
  528. Nexgen Pharma
  529. Nextar Chempharma Solutions
  530. Nimbles Biotech
  531. Ningbo Renjian Pharmaceutical Group 
  532. Nippon Rika Technologies
  533. Nipro Patch
  534. Nitin Lifesciences
  535. Nitto Avecia Pharma Services
  536. Nitto Denko Avecia
  537. Nivon Specialties
  538. Norac Pharma
  539. North Star Processing
  540. Norwegian Institute of Public Health
  541. Norwich Pharma Services
  542. Nova Laboratories
  543. NovaMed Pharmaceuticals
  544. Novartis
  545. Novasep
  546. Novel Laboratories
  547. Novex Innovations
  548. Nutragen Pharma
  549. NutraLab
  550. NVRON Life Science
  551. Oakwood Laboratories
  552. Oasis Laboratories
  553. Oceanic Pharmachem
  554. OctoPlus
  555. Olon
  556. Oman Pharmaceutical Products
  557. Omnia Biologics
  558. Onco Generics
  559. Oncotec Pharma Produktion
  560. OPKO Health
  561. Optel Vision
  562. Orchid Pharma
  563. Orient EuroPharma
  564. Orient Pharma
  565. Orion 
  566. Orofino Pharmaceuticals Group
  567. Oso BioPharmaceuticals Manufacturing
  568. Oxford BioMedica
  569. P&R Holding
  570. Pan American Health Organization (PAHO)
  571. Panacea Biotec
  572. PannonPharma 
  573. Parabolic Drugs
  574. Paragon® Bioservices
  575. Particle Sciences
  576. Patheon®
  577. PB-L Productos Bio-Lógicos
  578. PCI Synthesis
  579. PCT Cell Therapy
  580. Pegasus Farmaco India
  581. Penn United Industries
  582. Perrigo®
  583. Pfizer
  584. Pfizer CentreOne
  585. Pharma Stulln
  586. PharmaCell
  587. Pharmaceutical Associates
  588. Pharmaceutical Manufacturing Research Services (PMRS)
  589. Pharmaceutical Medical Devices Agency (PMDA)
  590. Pharmaceutics International (Pii)
  591. Pharmacia & Upjohn 
  592. PharmAgra Labs
  593. Pharma-Q
  594. Pharmascience
  595. Pharmasol
  596. Pharmatronic
  597. PharmaZell 
  598. Pharmedartis
  599. Pharmer
  600. Pharmicell
  601. Phenom-World 
  602. Phytex Australia
  603. Phyton Biotech
  604. Pierre Fabre
  605. Pillar5 Pharma
  606. Pinewood Healthcare
  607. Piramal Pharma Solutions
  608. PiSA Farmaceutica
  609. Pisgah Laboratories
  610. PlasmidFactory
  611. PMC Isochem
  612. Polpharma
  613. Polymun Scientific
  614. PolyPeptide Group
  615. Polysciences
  616. Porton Fine Chemicals
  617. Praxis Pharmaceutical
  618. Precision Antibody
  619. Preet Remedies Group
  620. PREMAS Biotech
  621. Prima BioMed 
  622. PrimaPharma
  623. Prisha Healthcare
  624. ProBioGen
  625. Procaps
  626. Procos
  627. Profectus BioSciences
  628. ProJect Pharmaceutics
  629. ProMab Biotechnologies
  630. Proton Pharma
  631. Provizer Pharma
  632. PRWT Services
  633. PT. ETHICA Industri Farmasi 
  634. Pure & Cure Healthcare
  635. PX'Therapeutics
  636. Pyramid Laboratories
  637. QS Pharma
  638. Qualigen
  639. Qualiphar-Gifrer
  640. Qualitron Bio Medica
  641. Quality Chemical Laboratories
  642. Qualtra Pharmaceuticals
  643. Quay Pharma
  644. Que Pharma
  645. Radico Remedies
  646. Rafarm
  647. Ramsey Design Group
  648. Rank Group
  649. Recipharm
  650. Redwing Pharma
  651. Regis Technologies
  652. Reliable Biopharmaceutical®
  653. Reliance Life Sciences
  654. Remington Pharmaceuticals
  655. Renaissance Acquisition Holdings
  656. Rentschler Biopharma
  657. ResearchPoint Global 
  658. Richter-Helm BioLogics
  659. RiconPharma
  660. RIVOPHARM
  661. RL Fine Chem
  662. Robert Wood Johnson Medical School
  663. Roche
  664. Rommelag
  665. Rompharm
  666. Roslin Cell Therapies
  667. Rottendorf Pharma
  668. Rubicon Research
  669. Rusan Pharma
  670. SAFC Pharma™ 
  671. SAI Life Sciences
  672. Salvus Pharma
  673. Sandoz
  674. Sanico
  675. SANOCHEMIA Pharmazeutika
  676. Sanquin Pharmaceutical Services
  677. Sanwa Kagaku Kenkyusho
  678. Sarvodaya Drugs & Pharmaceuticals
  679. Sarvotham Care
  680. Sato Pharmaceutical
  681. SAVA Healthcare
  682. Savior Lifetec
  683. Schering-Plough
  684. SCI Pharmtech
  685. Scientific Protein Laboratories
  686. ScinoPharm
  687. SEA Vision 
  688. Seacross Pharmaceuticals
  689. Sekisui Medical
  690. Selvok Pharmaceutical
  691. Senn Chemicals
  692. Sensilab®
  693. Sentiss Pharma
  694. Sesderma Group
  695. Shandong Xinhua Pharmaceutical
  696. Shanghai Pharmaceuticals Holding
  697. Shanghai Shyndec Pharmaceutical
  698. Sharon Bio-Medicine 
  699. Shasun Pharmaceuticals
  700. Shilpa Medicare
  701. Shionogi
  702. Shire
  703. Sichuan Huiyu Pharmaceutical 
  704. Siegfried
  705. Sigmapharm Laboratories
  706. SignaGen Laboratories
  707. Singota Solutions
  708. Sinopharm
  709. Sirio Pharma
  710. SM Pharmaceuticals
  711. Smruthi Organics 
  712. SMS Pharmaceuticals
  713. Societa Italiana Medicinali Scandicci
  714. Softgel Healthcare
  715. Softigel
  716. SOHO Global Health
  717. Solitaire Pharmacia
  718. Sovereign Pharma
  719. Square Pharmaceuticals
  720. Sricure Herbs
  721. ST Pharm
  722. STA Pharmaceutical
  723. STADA Arzneimittel 
  724. Stason Pharmaceuticals
  725. Stericon
  726. Steril-Gene Life Sciences
  727. Strides Shasun
  728. Sunrise International Labs
  729. Sunrise Pharma
  730. Sunways
  731. Suven Life Sciences
  732. Suzuken
  733. Swiss Pharma
  734. Symbiosis Pharmaceutical Services
  735. Symed Labs
  736. Synbias Pharma
  737. SynCo Bio Partners
  738. Syncom Healthcare
  739. Syngene International
  740. SYNLAB Group
  741. Syntech Pharmachem
  742. Synthokem Labs
  743. Syntonix Biofarm
  744. Tahira Industries India
  745. Tai Heng Industry
  746. Takara Bio
  747. Tara Innovations
  748. Tedor Pharma
  749. Teligent
  750. TESARO
  751. Teva Active Pharmaceutical Ingredients (TAPI)
  752. The Carlyle Group 
  753. The Native Antigen Company
  754. The Ritedose
  755. Theon Pharmaceuticals
  756. Therapeutic Goods Administration (TGA)
  757. Therapure Biopharma
  758. Thermo Fisher Scientific
  759. Tianjin Pharmaceutical Group
  760. Tillotts Pharma
  761. Time-Cap Labs
  762. Titan Pharma
  763. TOLMAR
  764. Tonus-Les
  765. Torrent Pharmaceuticals
  766. Toyobo Biologics
  767. TraceLink
  768. TranXenoGen
  769. trenzyme
  770. Tubilux Pharma
  771. Tyger Scientific
  772. Ultra Tab Laboratories
  773. Ultratech India
  774. Unibiotech Formulations
  775. Unichem Laboratories
  776. Unimark Remedies
  777. Union Quimico Farmaceutica (UQUIFA)
  778. Unison Chemical Works
  779. United States Food and Drug Administration (USFDA)
  780. University of Alabama
  781. University of Minnesota
  782. University of Nebraska
  783. University of Newcastle
  784. University of Pennsylvania
  785. University of Utah
  786. UPM Pharmaceuticals
  787. Uppsala University Hospital
  788. URSAPHARM Arzneimittel
  789. US Pharma Lab
  790. USV
  791. Valeant Pharmaceuticals International
  792. Veeva Systems
  793. Vendiz Pharmaceuticals
  794. VerGo Pharma Research
  795. Vertex Pharmaceuticals 
  796. Vetter Pharma
  797. VGXI
  798. Vibalogics
  799. Vigene Biosciences
  800. Virbac
  801. Virovek
  802. Vista Biologicals
  803. Vital Health Care
  804. Vivimed Labs
  805. VUAB Pharma 
  806. WACKER Biotech
  807. Waisman Biomanufacturing
  808. Wanbury
  809. WellSpring Pharmaceutical
  810. West Pharmaceutical Services
  811. WeylChem Group
  812. Wilmington PharmaTech
  813. Windlas Healthcare
  814. Wintac
  815. Wisdom Pharmaceutical
  816. Wockhardt
  817. World Health Organization (WHO)
  818. World Intellectual Property Organization (WIPO) 
  819. World Trade Organization (WTO)
  820. Wuhan Biocause Pharmaceutical Development
  821. WuXi AppTec
  822. WuXi NextCODE
  823. Xellia Pharmaceuticals 
  824. Xi'an Lijun Pharmaceutical 
  825. XtalPi
  826. Xttrium Laboratories
  827. YaoPharma
  828. Yash Pharma Laboratories
  829. Yung Zip Chemical
  830. Zach System
  831. Zambon
  832. Zenacts Pharma
  833. Zenara Pharma
  834. Zenith Healthcare
  835. ZenLabs Ethica
  836. ZheJiang Apeloa JiaYuan Pharmaceutical
  837. Zhejiang Changming Pharmaceutical
  838. Zhejiang Cheng Yi Pharmaceutical
  839. Zhejiang Excel Pharmaceutical
  840. Zhejiang Hisun Pharmaceutical
  841. Zhejiang Huahai Pharmaceutical
  842. Zhejiang Huangyan Fine Chemical Group
  843. Zhejiang Jingxin Pharmaceutical
  844. Zydus BSV Pharma
  845. Zydus Cadila
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com